Jasper Therapeutics Announces Oral Presentation Of Final Results From Phase 1 Study Of Briquilimab In Patients With AML Or MDS Undergoing Hematopoietic Cell Transplant At ASH 2023
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics (NASDAQ:JSPR) announced positive final results from the Phase 1 study of briquilimab in combination with fludarabine and low-dose irradiation conditioning in older adults with acute myeloid leukemia (AML) in complete remission or myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplant. The results will be presented at the America Society of Hematology (ASH) 2023 Annual Meeting & Exposition. The study demonstrated that a regimen of briquilimab plus Flu/TBI leads to successful engraftment of donor blood stem cell without the associated short and long-term toxicities.
November 02, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Positive results from Jasper Therapeutics' Phase 1 study of briquilimab could potentially boost investor confidence and the company's stock price.
Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. In this case, the successful Phase 1 results for Jasper Therapeutics' briquilimab, a treatment for AML and MDS, could potentially have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100